<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 345 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page344.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=345">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 345 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 345</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=345"><img src="../thumb/345.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>308 / 2020-04                                                           Endocrine System - 19.7
   Male: Gynaecomast., acne, weight gain, admin. site reacts.,   opthy, Prader-Willi syndr.who are sev.obese or have resp.impairm.,   ser.oestrad.lev.reg. mimim. OHSS/multip.pregn.risk, self-admin.
   hypersens.                   uncontrol.or poorly control. type I & II diab.mellit., pregn.& lactat.  only with expert advice access., monit.porhyr./family hist. thereof
   Warnings and special precautions: For use only by physic.  Side effects: Uncomm: Headache, loc.reacts. Rare: Rash, ar-  & discont.treatm.if deteriorat./first appear. of condit., cont.sucrose,
   famil.with infertil., reg.monit.of ovar. respons., eval.pts.for pregn.  thralg., myalg., periph.oed., Unknown: Mild arthralg.,musc.pain,   confirm infertil. diagnos.as hypogonadotroph.hypogonadism & excl.
   CI/hypothyroid./ adrenocortic. defic./hyperprolactinaem & pituit.  paraesthes., benign intracran.hypertens., hypothyroid., slipp. capit.  hypothyroid./adrenocort.insuffic./ hyperprolactinaem./ pituit.& hypo-
   or hypothalamic tumours giv.appropr.specif.treatm., rupt. risk with   femor.epiphys., Legg-Clavé-Perthes dis.poss. more freq.in pts.  thal.tumours bef. init. ther., ovar.hyperstimulat.risk, monit.for S&S of
   ovar.enlargem.theref.pelv.examin.to be avoid/carefully perform.,   with short stature  ovar. hyperstimulat.syndr., withhold hCG admin. if ovar.hyperstimulat.
   withhold hCG admin.in case of excess.ovar.respons.& pts.to be   Warnings and special precautions: Verify diagn. by pituit.funct.  develops & avoid coitus/use barr. methods for at least 4 days, foll.
   advis.to refrain from coitus/use barr.method x4 days, monit. pts.x2   bef.admin., treatm.only effect. if epiphyseal fus.has not taken place,   pts.for at least 2 wks.aft.hCG admin., advis.pt.bef.init.ther.of po-
   wks.aft.hCG admin.for OHSS, high. OHSS preval.in polycyst.ovar.  discont. if recurr.tumour growth evident, monit. pts.reg.if growth   tent. incr.multipl. pregn./birth risk, discont. treatm. & spec.ther.init.
   dis., multiple pregn., miscarr./ abort.incid.& ectop.pregn.high.than   horm.defic.is second.to an intracran. les., childr.to be reg.assess. by   should sev.OHSS occur, incr. OHSS incid.in polycyst.ovar.dis., high.
   for norm. populat., ovar.& other reproduct.syst. neoplasms report.,   a specialist in child growth, fatalit.report.in paed. Prader-Willi syndr.  incid.of miscarriage/ abort.report., tubal dis.hist., benign & malign.
   congenit.malformat.preval. slightly. high., incr.risk.of ven./arter.  pts., eval.Prader-Willi syndr.pts. for upper airway obstruct.& sleep   ovar.& other reproduct.system.neoplasms report., slight.high.preval.
   thromboembol. events, lact.intol.  apnoea bef.init. treatm. & cont.dur.treatm.tog.with weight control,   of congenit.malformat., incr.risk of thrombo-embol.events.if risk fact.
   Interactions:. Incr.risk of ovar. hyperstimulat. syndr. in women who   discont. if upper airway obstruct.(incl.snoring) & new onset sleep   preval., independ.OHSS risk fact.incl.young age/ lean body mass/
   show.evid.of excess.ovar. stimulat. while receiv.luteinis.hormone,   apnoea occ., Prader-Willi syndr. pts.to have effect.weight contr &   polycyst.ovar.syndr./high. Pergoveris dos., high absol.or rapid.ris.ser.
   concom. clomiphene citrate may enhanc.follicul.respons.  monit.for signs of resp.infects., monit.pts.who have achiev.complete   oestrad. lev.& prev.OHSS episod./large numb.of develop. follicles &
   See also MDR page 330.       remiss. from malign.dis.caref., test pts.fail.to respond for antibod.,   large numb.of oocytes retriev. in ART cycles.
   MERIONAL HG, Delfran         diab.mellit./hist.thereof, monit. gluc.tol.pre- & dur.treatm., discont.  See also MDR page 505.
                                treatm.in diagn. of benign.intracran.hypertens., period. thyroid test.,
   Menotrophin equiv.to FSH     discont.if pregn.occurs.      PREGNYL, MSD
   Indications: Anovulat. (incl. PCOD) in women unrespons.to clo-  Interactions: Eff.poss.inhibit.by concom. glucocortic. ther, other   Chorionic gonadotrophin
   mifene., multifollicul.developm.in assist. reproduct.technolog..  addit.hormones (incl. gonadotropin, anabol.ster., oestrogen & thyr.   Indications: Female: Ovulat.induct.in sub-fertility due to ano-
   (S4) INJ, 48/21.10/0402      hormone) may influence eff.on final height.  vulat./imp.follic.-ripen., prep.of follicl. for punct.in controll.ovar.
   3001215-001: 75 IU, sngl.vial, R249,96                     hyperstimulat. programm. (for medically assist.reproduct.techniq.),
   3001215-002: 75 IU, 10 vials, R2 499,56  OVITRELLE 250 µg/0,5 ml, (Biopharma Div) Merck [N/P/S   luteal phase supp.
   Dosage: Admin.as IM/SC inj.accord.to manufact.lit.  for males] &  Male: Hypogonadotroph.hypogonadism, delay. puberty assoc.
   Wom.with anovulat. (incl. PCOD): Treatm.may be giv. as course   Choriogonadotrophin alfa  with insuffic.gonadotroph.pituit. funct., cryptorchid.not due to
   of dly.injects. Start treatm.in menstruat.pts.within first 7 days of   Indications: In women undergo.superovulat.prior to assist.reprod-  anatomic.obstruct..
   menstr.cycle. Adjust.treatm.to individ.response as assess.by meas.   uct.techniq.to trigg.final follicul. maturat.& luteinisat.aft.follicul.  (S4) POWD.FOR SOL.FOR INJ., G3202, G3203
   follicle size by ultrasound &/oestrog.secret.  growth stimulat., to trigg.ovulat.& luteinisat.in anovulat./oligo-  756652-006: 1500 IU 3’s, R256,76
   Common.used regim: 75–150 I.U. adjust.accord. to pt.respon.   ovulat. pts.aft.follicul.growth stimulat.  756660-010: 5000 IU 1’s, R184,06
   Max.dly.dos.usual.not high.than 225 I.U. When ideal resp.obtain.  (S4) INJ. A41/21.10/0523  3000467-001: 5000 IU 2’s, R368,11
   admin.sngl hCG inj.of 5 000 – 10 000 I.U. 24 – 48 hrs.aft.last inj. If   717380-001: 250  µg equiv.to approx.6 500  IU,   Dosage: Admin.by slow IM or SC inj.
   respons.inadeq.aft.4 wks.of treatm.abandon cycle and recommenc.  1x pre-fill.syr., R431,19  Females: Ovulat.induct./preparat.of follic.for punct.: 1 x 5000
   at high.init.dos.than prev.cycle.  3000086-001: 250 µg, 1x0,5ml pre-fill.syr., R431,19  - 10000 I.U. inj.to complete treatm. with an FSH- contain.prep.
   Wom.with anovulat.result. from sev.LH & FSH defic: Treatm   Dosage: SC admin. Treatm.to be und.supervis.of exper. physic.  Luteal phase supp.: 2–3 repeat inj.of 1000 - 3000 I.U. each may
   may commence at any time. Adjust.treatm.to individ.response as as-  Superovulat.prior to assist.reproduct.techniq: 250 µg 24-  be giv.within 9 days follow. ovulat./embryo transfer (eg. on day 3,
   sess.by meas. follicle size by ultrasound &/oestrog.secret.   48 hrs.aft.last FSH/hMG prep.admin.  6 and 9 aft. ovulat.induct).
   Common.used regim: 75 – 150 I.U.adjust. accord. to pt.resp. Incr.  Anovulat./oligo-ovulat.women: 250 µg 24-48 hrs. aft.optim.  Males: Hypogonadotroph.hypogonad.: 1000–2000 I.U. 2–3x /
   dos.in 150 I.U.increms.aft. 7–14 day intervals. Durat. of stimulat.in   stimulat.of follicul.growth achiev. Coitus recomm.on day of and   wk. In sub-fertil.addit.doses of an FSH contain.preparat. (75 I.U. FSH)
   any one cycle may be extend.up to 5 wks. When ideal respon. ob-  day aft.admin.  dly/2–3x /wk. may be giv. Contin.for at least 3 mnths.bef.expect. any
   tain.admin.sngl.hCG inj.of 5 000 – 10 000 I.U. 24–48 hrs.aft.last inj.   Contraindications: Hypothalamus & pituit.gland tumours, ovar.  improvem.in spermatogenes. . Suspend testoster. replacem.ther.dur.
   If respons. excess. suspend.treatm.& withhold hCG recommenc.   enlargem./cyst other than polycyst. ovar.dis., gynaecolog.haemorrh.  this treatm. Improvem. may sometimes be maintain.by hCG alone.
   next cycle at low.dos.       of unknown aetiology, ovar./uter.or mammary Ca, extra-uter. pregn.   Delayed puberty: 1500 I.U. 2–3x /wk. for at least 6 mnths.
   Wom.underg.controll.ovar.stimulat.for multip. follicul.de-  dur.prev.3 mnths, rec.thrombo-embol. disords./ hist.thereof., con-  Cryptorchidism: &lt;2 yrs of age: 250 I.U. 2x /wk. for 6 wks.; &lt;6 yrs.
   velopm.prior to in vitro fertilisat./ other assist.reproduct.  dits.where effect. respons. not poss., pregn.& lactat.given indicat.  of age: 500 - 1 000 I.U. 2x /wk. for 6 wks.; &gt; 6 yrs. of age: 1 500
   technolog: Admin. 150-225 IU dly.start.on days 2-3 of cycle, cont.   Side effects: Ectop.pregn.& ovar.torsion consid.concom.effs.of ART.  I.U. 2x /wk. for 6 wks. Repeat if necess.
   treatm. until.adeq.follicul.developm.achiev. adjust.dos. accord. to re-  Common: N&V, abdom.pain, mild-mod.ovar. hyperstimulat.syndr.,   Contraindications: Known/suspect.androgen-depend.tumours
   spons.usual.not high.than 450 IU dly. Gen adeq.follucul.developm.  headache, tiredn., loc. reacts./inj.site pain. Uncommon: Depress.,   incl.prostat.Ca./breast Ca.in the male, lactat., pregn.: may be used
   achiev.by 10th day within range of 5 -20 days. To induc.fin. follicul.   irritabil., restlessn., diarrh., sev.ovar.hyperstimulat. syndr., breast   for luteal phase supp.
   maturat.admin.sngl.inj.of 10 000 IU of hCG 24-48 hrs.aft.last inj.  pain. V.rare: Allerg.reacts., mild revers. skin reacts., thromboembol.  Side effects: Inject.site react., allerg.reacts.incl. fev./rash. Fe-
   When pituit.down regulat.with GnRH is used init. treatm. 2 wks.  Warnings and special precautions: No exper. in other indicat.  males: unwant.ovar.hyperstimulat., ovar.hyperstimulat.syndr.
   aft.start of agon.treatm.then contin. with both until adeq.follic.   common.treat.with urine deriv. human chorion.gonadotrophin, bef.  Males: water & Na+ retent. aft.admin.of high dos.as a result of
   developm. achiev.            init.treatm: assess. coupl.infertil., eval.C/I for pregn., eval.esp. for   excess. androgen product., gynaecomast.
   Contraindications: Pregn.& lactat., childr., hypothalam./pituit.  hypothyroid./adrenocortic.defic./ hyperprolactinaem. & pituit.or   Warnings and special precautions: Females: Incr.risk of mul-
   gland tumours, ovar.enlargem./ cyst not due to polycyst.ovar.dis.,   hypothalam. tumours and give appropr.specif.treatm., exist. clinic.   tiplets, poss.incr.incid.of ectopic pregn., early ultrasound confirmat.
   gynaecolog. bleed. of unknown origin., ovar./uter./breast Ca, where   signif.system.dis.which poss.worsens with pregn., self-admin.only   that pregn.is intrauter., incr.rates of pregn.loss in women underg.
   effect.respons.cannot be achiev.eg. prim. ovar. fail./sex.organ mal-  aft.adeq.train.& und. supervis., incr.ovar.hyperstimulat.syndr.risk,   ART, rule out presence of uncontroll.non-gonadal endocrinopath.
   format/uter.fibroid tumours imcompat.with pregn.  withhold hCG admin.in case of excess.ovar. respons. & pts.to be   incl.thyr./adren./pituit. disords., unwant.ovarian hyperstimulat. aft.
   Side effects: Freq: Headache, abdom.pain/ cramps, N&V, diarrh.,   advis.to refrain from coitus/ use barrier method for at least 4 days,   prior FSH admin.,  do not admin.Pregnyl & avoid pregn. in case of
   bloat., acne, ovar.cysts, OHSS, weight gain, inj. site reacts. Less   monit. oestradiol lev.& ovar.respons.based on ultrasound recomm.   unwant.ovarian hyperstimulat., pts.at incr. risk of ven./arter.thrombo-
   freq: System. allerg.reacts., thromboembol., ovar. torsion.  prior to & dur.stimulat.ther., eval.benef. vs risk when thromboembol.  embol.events, do not use for body weight reduct.as ineffect. Males:
   Warnings and special precautions: Only for use by exper.   risk fact./hist.pres., multip. pregn./miscarr.risk., no clinic.data avail.  latent/overt card.fail./ren.dysfunct./hypertens./ epilep./ migraine or
   physic., monit.ovar.respons.with ultrasound & ser.oestrad.lev., as-  on expos.pregn./excret.in milk,   hist.thereof., caut.in pre-pubert. boys to avoid premat.epiphys. clos./
   sess.couple’s infert.as appropr & eval.putat.C/I’s for pregn., eval.   Interactions: Poss. false pregn.test for up to 10 days aft.admin.,   precoc. sex.developm. & monit.skelet.maturat.reg.
   for hypothyroid./adrenocortic.defic./ hyperprolactinaem./ pituit.or   min.thyroid stimulat.poss.but clinic.relev.unknown.
   hypothalamic tumours, ovar.hyperstimulat.syndr.risk, withhold hCG   See also MDR page 504.  PUREGON, MSD [P/S]
   admin.if ovar.hyperstimulat.develops & avoid sex. intercourse x4   PERGOVERIS, (Biopharma Div) Merck [N/P/S in males] &  Recombinant follicle-stimulating hormone (FSH) (follitropin beta)
   days, multip.pregn.risk., high. incid. of miscarriage/abort.report.,   Indications: Fem.infertil.in anovulat.in women unrespons.to treatm.
   high.ectop. pregn. risk, benign & malign.ovar.& other reproduct.   Follitropin alfa 150 IU, lutropin alfa 75 IU/ ml  with clomifene citrate/ controll. ovar. hyperstimulat.to induce devel-
   system.neoplasms report., high.preval. of congenit.malformat.  Indications: Stimulat.of follicul.developm.in women with sev.  opm.of mult.follic.in medic.assist.reproduct.progs.
   thought to be due to differ. in parent.characterist.( e.g matern.age)   LH & FSH defic.  (S4) SOL.FOR INJ., 35/21.10/0135, 35/21.10/0016, 0017.
   & multip. pregn., incr.risk of thrombo-embol.events.in pts. with   (S4) INJ, 44/21.10/0781  858722-004: 50 IU, 1x0,5 ml cart., R216,42
   gener.recognis.risk fact., lactose intol., do not. admin.as mixt. with   717165-001: 150 IU/ 75 IU, 1 vial + solv., R559,56  721279-001: 300 IU, 1x0,36 ml cart., R1269,27
   other meds.in same inj.      Dosage: Admin.low.effect.dos.in relat.to treatm. obj. Not to be   720629-001: 600 IU, 1x0,72 ml cart., R2 538,56
   Interactions: Concom.use with other ovulat. stimul. agents may   admin.as a mix.with other meds.in same inj. except.r-hFSH. Assess   Dosage: Admin.by slow IM or SC inj. (50 IU)/ SC by Puregon Pen
   potent.follicul.respons., poss. dos. incr.need.to elicit adeq.ovar.re-  respons.by ultrasound & oestrog.respons.  (300/600IU); indiv.depend.on ovar. respon., monit.ovar.respon.by ul-
   sponse with concom. gonadotroph releas.horm.agon.  Indiv. Init: admin.SC inj.1 vial dly. Altern.sites dly. If FSH dos.incr.  trasonography & plasma oestrad.lev.measurem., altern.SC inj.site.to
                                                              prev.lipoarthrophy. Clinic.exper.bas.on up to 3 treatm. cycles. Exper.
                                appropr.adapt pref.aft.7-14 day interv. by 37,5-75 IU increm using
   NORDITROPIN NORDILET, Novo Nordisk  regist.r-hFSH prep. May extend stimulat.durat.in any one cycle up to   indic.success.declines aft.1  4 attemtps.
                                                                          st
   Somatropin.                  5 wks. Sngl inj.of 5 000-10 000 IU hCG should be admin. 24-48 hrs   Anovulation: Init.50 IU FSH activity dly. x at least 7 days. If no ovar.
   Indications: Growth fail.in childr.due to somatropin defic., Turn-  aft.last Pergoveris inj. when optim.respons.obtain. Coitus recomm.  respon.incr. dly.dos.grad. until follic.growth &/or plasma oestrad.
   er syndr.                    on the day of & the day follow hCG admin.or intra-uter. insemin.  lev.incr.by 40-100%/day. Maint.dos.for 7-14 days unt.pre-ovulat.
   (S5) SOL.FOR INJ, 33/21.10/0420, 0421  perform.,consid.luteal phase support, Treatm.to be stop.& hCG   condits.reach.(ultrasonograph.evid.of dominant follic.&gt;= 18 mm
   704017-001: 5 mg/1,5 ml, 1xmulti-dos.dispos.pre-fill.pen., R1 178,77  withheld if an excess. repons.obtain.  in diamet. &/ plasma oestrad.lev of 300-900 picog./ml). Discont &
   704018-001: 10 mg/1,5 ml, 1xmulti-dos.dispos. pre-fill.pen,   Contraindications: Hypothalam./ pituit. tumours, ovar.enlargem./  induc.ovulat.by admin.hCG.; decr.dly.dos if nr.of respond.follic.too
   R2 357,68                    cyst not due to polycyst. ovar.dis., gynaecolog.bleed.of unknown ori-  high/oestrad.lev.incr.too rapid.; multiple pre-ovulat. follic.exceed.14
   Dosage: Individ.dos.accord.to bm/m /respon.to ther. Dly.SC admin.  gin., ovar./uter./ breast Ca, prim.ovar.fail., sex.organ malformat./ uter.  mm carry risk of multiple gestat., hCG should be withheld & pregn.
                  2
   in even.recomm. Vary inj.site to prev.lipo-atrophy. Nordilet dos.deliv.  fibroid tumours incompat.with pregn., pregn. & lactat.  avoid.to prev.multipl.gestat.
   in clicks. Dos. per click is 0,0667 mg for 5 mg/1,5 ml and 0,1333 mg   Side effects: Headache, asthma exacerbat., GI disturbs., throm-  Control.ovar.hyperstimulat.in medic. assist. reproduct. pro-
   for 10 mg/1,5 ml.            boembol.usual.assoc.with sev. OHSS, loc.reacts.at inj.site, syst.  grammes: 100 - 225 IU recommend. for 1st 4 days at least. There-
   Growth hormone defic: 25-35 µg/kg/day (0,070-0,10 IU/kg/day).  allerg.reacts. somet. ser.incl.anaphylact.reacts.& shock, ovar. cyst,   aft. adjust. indiv.bas.upon ovar.respon. Maint.dos.: 75 – 375 IU X
   Turner syndr: 50 µg/kg/day (0,14 IU/kg/day).  breast/pelv.pain, mild to sev.ovar. hyperstimulat. syndr., ovar.tor-  6-12 days; Can be giv.alone or in combinat. with GnRH agonist to
   Contraindications: Act.tumour, ac.critic.illn. suffer. from compli-  sion, ectop.pregn.  prev.premat. luteinisat.; when combin.with GbRH agon. High. tot.
   cat.follow.open heart surg./ abdom. surg./multipl.accident.trauma/  Warnings and special precautions: Only for use by med.  treatm.dos.may be reqd.if ultrasonograph.eval. indicat at least 3 fol-
   ac.resp.fail. or similar condits., proliferat.or preproliferat.diab. retin-  practit.famil.with infertil., monit.ovar. respons. with ultrasound &   lic.of 16-20mm & good oestrad. respon.evid (plasma lev. of 300-400</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page344.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page340.html">340</a>&nbsp;&nbsp;&nbsp;<a href="page341.html">341</a>&nbsp;&nbsp;&nbsp;<a href="page342.html">342</a>&nbsp;&nbsp;&nbsp;<a href="page343.html">343</a>&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>&nbsp;&nbsp;&nbsp;<a href="page350.html">350</a>
             </td>
             <td width="35%"><a href="page346.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page346.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
